Combivent Coupons

LONDON, Nov. 14, 2017 /PRNewswire/ -- Download the full report:

The global asthma & COPD therapies market was valued at $32.9bn in 2016 and is projected to grow at a CAGR of 5.6% in the first half of the forecast period. The Anti-inflammatory Drugs submarket will be the fastest growing submarket in the first half of the forecast period. This submarket is estimated to grow at a CAGR of 7.6%.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 300-page report you will receive 113 tables and 130 figures – all unavailable elsewhere.

The 300-page report provides clear detailed insight into the global asthma & COPD therapies market. Discover the key drivers and challenges affecting the market.

Report Scope

-Global Asthma & COPD Therapies Market forecasts from 2017-2027, further broken down into:- Global Asthma Therapies Market forecasts- Global COPD Therapies Market forecasts

-Revenue forecasts of the three main drug classes of the global asthma & COPD therapies market:

- Bronchodilators monotherapy

- Anti-inflammatory drugs

- Combination drugs

• Revenue forecast for the Bronchodilators monotherapy market by Type and revenue forecast of the leading drugs:- Short-acting beta2-agonists (SABAs): Ventolin, ProAir, Proventil, Xopenex- Long-acting beta2-agonists (LABAs): Brovana, Foradil, Arcapta/Onbrez, Serevent,- Anticholinergics: Spiriva, Atrovent, Eklira/Tudorza/Bretaris

• Revenue forecast for the Anti-inflammatory drugs market by Type and revenue forecast of the leading drugs:

- Corticosteroids: Pulmicort, Flixotide/Flovent, QVAR, Asmanex

- Anti-leukotrienes: Singulair

- Monoclonal antibodies (mAbs): Xolair, Cinquil/Cinquair, Nucala, Benralizumab, Lebrikizumab, Dupilumab

• Revenue forecast for the Combination drugs market and the leading drugs:- Advair/Seretide, Symbicort, Combivent, Dulera, Relvar/Breo

• This report provides individual revenue forecasts from 2017-2027 for these regional and national markets:

- The US

- Japan

- EU5: Germany, France, UK, Italy, Spain

- BRIC: Brazil, Russia, India, China

- Mexico

- Other Countries

• This report discusses the leading companies in the global asthma & COPD therapies market:- GSK- Boehringer Ingelheim- AstraZeneca- Novartis- Merck- Roche- Teva

• This report discusses drugs currently in clinical development for treating asthma and COPD.

• This report discusses the SWOT analysis as well as porter's five forces analysis of the global asthma & COPD therapies market.

Download the full report:

About Reportbuyer

Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers

For more information:

Sarah Smith

Research Advisor at


Tel: +44 208 816 85 48



View original content:

SOURCE ReportBuyer

Source :$32-9bn-In-2016-1008080725

The Global Asthma & Copd Therapies Market Was Valued At $32.9bn In 2016
Joe Hadsall: Inhaler-makers can't leave well enough alone
FDA phasing out asthma inhalers using CFC propellant
No more Primatene Mist in the U.S. after this year
PITTSBURGH CITY PAPER 04.22/04.29.2015
Reversing JFK: Santorum’s bid to marry faith and politics
President signs law dealing with backlog of rape kits
Breathe a little easier
[LIMITED STOCK!] Related eBay Products